Zura Bio Net Worth
Zura Bio Net Worth Breakdown | ZURA |
Zura Bio Net Worth Analysis
Zura Bio's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Zura Bio's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Zura Bio's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Zura Bio's net worth analysis. One common approach is to calculate Zura Bio's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Zura Bio's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Zura Bio's net worth. This approach calculates the present value of Zura Bio's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Zura Bio's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Zura Bio's net worth. This involves comparing Zura Bio's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Zura Bio's net worth relative to its peers.
To determine if Zura Bio is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Zura Bio's net worth research are outlined below:
| Zura Bio Limited generated a negative expected return over the last 90 days | |
| Zura Bio Limited has high historical volatility and very poor performance | |
| Net Loss for the year was (60.56 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Zura Bio generates negative cash flow from operations | |
| Zura Bio Limited has a poor financial position based on the latest SEC disclosures | |
| About 32.0% of the company outstanding shares are owned by insiders | |
| Latest headline from simplywall.st: Were Hopeful That Zura Bio Will Use Its Cash Wisely |
Zura Bio uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Zura Bio Limited. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Zura Bio's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 10th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow Zura Bio's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 295.78 M.Market Cap |
|
Project Zura Bio's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.60) | (0.57) | |
| Return On Capital Employed | (0.78) | (0.74) | |
| Return On Assets | (0.60) | (0.57) | |
| Return On Equity | (1.02) | (0.97) |
When accessing Zura Bio's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Zura Bio's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Zura Bio's profitability and make more informed investment decisions.
Please note, the presentation of Zura Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Zura Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Zura Bio's management manipulating its earnings.
Evaluate Zura Bio's management efficiency
Zura Bio Limited has return on total asset (ROA) of (0.214) % which means that it has lost $0.214 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3685) %, meaning that it created substantial loss on money invested by shareholders. Zura Bio's management efficiency ratios could be used to measure how well Zura Bio manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.57. The current year's Return On Capital Employed is expected to grow to -0.74. At present, Zura Bio's Other Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 105.9 M, whereas Total Assets are forecasted to decline to about 90.6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.41 | 2.67 | |
| Tangible Book Value Per Share | 2.41 | 2.67 | |
| Enterprise Value Over EBITDA | (0.73) | (0.69) | |
| Price Book Value Ratio | 2.42 | 2.30 | |
| Enterprise Value Multiple | (0.73) | (0.69) | |
| Price Fair Value | 2.42 | 2.30 | |
| Enterprise Value | 39.6 M | 35.2 M |
The strategic initiatives led by Zura Bio's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Return On Equity (0.37) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zura Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zura Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Zura Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Zura Bio Corporate Filings
8K | 25th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 16th of September 2024 Other Reports | ViewVerify | |
F4 | 13th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Zura Bio Earnings per Share Projection vs Actual
Zura Bio Corporate Management
| Gary Whale | Chief Officer | Profile | |
| David Brady | Head Development | Profile | |
| Kiran MBBS | Chief Development | Profile | |
| Kimberly Davis | Chief Secretary | Profile | |
| Theresa Lowry | Chief Officer | Profile | |
| Verender Badial | Chief Officer | Profile | |
| Michael Howell | Chief Medicine | Profile |
Already Invested in Zura Bio Limited?
The danger of trading Zura Bio Limited is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Zura Bio is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Zura Bio. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Zura Bio Limited is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Zura Bio Limited offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zura Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zura Bio Limited Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zura Bio Limited Stock: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zura Bio Limited. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zura Bio. If investors know Zura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zura Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.57 | Return On Assets (0.21) | Return On Equity (0.37) |
The market value of Zura Bio Limited is measured differently than its book value, which is the value of Zura that is recorded on the company's balance sheet. Investors also form their own opinion of Zura Bio's value that differs from its market value or its book value, called intrinsic value, which is Zura Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zura Bio's market value can be influenced by many factors that don't directly affect Zura Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zura Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zura Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zura Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.